AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 2642546
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment with CCNU and radiation therapy
Trial: 31046185
Drug: Physical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical therapy including desensitization maneuvers of the central nervous system
Trial: 21925959
Drug: Medication review
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication review intervention delivered by pharmacists
Trial: 19587607
Drug: beta-Blockers
RxNorm normalized name: BETA-BLOCKERS,TOPICAL OPHTHALMIC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: beta-Blockers
Trial: 16625984
Drug: Dexibuprofen (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexibuprofen (400 mg t.i.d for 3 days, then 400 mg b.i.d for 11 days)
Trial: 16625984
Drug: Ibuprofen (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen (800 mg t.i.d for 3 days, then 800 mg b.i.d for 11 days)
Trial: 16625984
Drug: Diclofenac (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac (50 mg t.i.d for 3 days, then 50 mg b.i.d for 11 days)
Trial: 16625984
Drug: All groups
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All groups (Dexibuprofen, Ibuprofen, Diclofenac)
Trial: 15630183
Drug: Rosmarinic acid
RxNorm normalized name: ROSMARINIC ACID
DrugBank: Rosmarinic acid (DB16865)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosmarinic acid (RA) 200 mg or 50 mg
Trial: 9205786
Drug: Cefodizime 2
RxNorm normalized name: cefodizime
DrugBank: Cefodizime (DB13470)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefodizime 2 g once daily (either intravenously or intramuscularly)
Trial: 2891372
Drug: 16-phenoxy-W-17, 18,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 16-phenoxy-W-17, 18, 19, 20-tetranor PGE2 methyl sulfonylamide (three intramuscular injections of 0.5 mg at 3-h intervals)
Trial: 29395279
Drug: OTO‐201 (ciprofloxacin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OTO‐201 (ciprofloxacin otic suspension 6%) intraoperative injection
Trial: 28629473
Drug: Intravenous phenytoin
RxNorm normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous phenytoin (20 mg/kg, maximum 2 g)
Trial: 28629473
Drug: Intravenous levetiracetam
RxNorm normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenous levetiracetam (40 mg/kg, maximum 2.5 g)
Trial: 20921467
Drug: Concurrent therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent therapy (paclitaxel 225 mg/m² and carboplatin AUC 6 every 3 weeks plus cetuximab 400 mg/m² loading dose followed by 250 mg/m² weekly for four cycles)
Trial: 20921467
Drug: Sequential therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential therapy (paclitaxel-carboplatin for four cycles followed by cetuximab)
Trial: 19099714
Drug: Inhaled Nitric
RxNorm normalized name: nitric oxide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled Nitric Oxide (iNO) at 15 ppm for 34.90 ± 16.41 hours
Trial: 17213687
Drug: Long-term air-conditioning
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term air-conditioning exposure (L)
Trial: 12648193
Drug: Music in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Music in combination with therapeutic suggestions (M/TS)
Trial: 10922094
Drug: Oral preparation
RxNorm normalized name: Iron bivalent, oral preparations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral preparation (45 mL oral sodium phosphate and 10 mg bisacodyl)
Trial: 10922094
Drug: Enema preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enema preparation (2 Fleet enemas and 10 mg bisacodyl)
Trial: 8141211
Drug: Amoxicillin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin (500 mg three times daily for 7 days)
Trial: 3410567
Drug: Sodium concentration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium concentration at 139 mmol/l
Trial: 21148631
Drug: Sodium oxybate
RxNorm normalized name: Sodium Oxybate
DrugBank: Sodium oxybate (DB09072)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium oxybate (SXB) 3 g per night for five consecutive nights
Trial: 16816220
Drug: Mirtazapine (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirtazapine (up to 60 mg/day)
Trial: 16816220
Drug: Nortriptyline (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nortriptyline (up to 200 mg/day)
Trial: 12705063
Drug: Selective cyclooxygenase‐2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective cyclooxygenase‐2 inhibitor (celexocib)
Trial: 12705063
Drug: Non steroidal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non steroidal anti‐inflammatory drugs (NSAIDs)
Trial: 12705063
Drug: Aspirin®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin®
Trial: 8527613
Drug: etodolac 300
RxNorm normalized name: etodolac 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: etodolac 300 mg b.d.
Trial: 20495139
Drug: Phenylephrine 50
RxNorm normalized name: phenylephrine 50 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenylephrine 50 μg/min
Trial: 31107542
Drug: Dose‐intensified radiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose‐intensified radiotherapy plus capecitabine and oxaliplatin (CAPOX50)
Trial: 28002167
Drug: Haloperidol 1
RxNorm normalized name: haloperidol 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol 1 mg intravenously
Trial: 26226960
Drug: PQQ disodium
RxNorm normalized name: BALSALAZIDE DISODIUM
DrugBank: Balsalazide (DB01014)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PQQ disodium salt (BioPQQ™) at an oral dosage of 20 mg/d for 12 weeks
Trial: 26226960
Drug: PQQ disodium
RxNorm normalized name: BALSALAZIDE DISODIUM
DrugBank: Balsalazide (DB01014)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PQQ disodium salt (BioPQQ™) in high LDL-chol subgroup (baseline LDL-chol ≥140 mg/dL)
Trial: 20077733
Drug: JEV‐I (PHK)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JEV‐I (PHK) vaccine
Trial: 20077733
Drug: Control vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control vaccine (Vero cell-derived JEV vaccine)
Trial: 17275282
Drug: Dexamethasone 4
RxNorm normalized name: dexamethasone 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 4 mg and droperidol 0.625 mg (combination)
Trial: 2913182
Drug: Internal Medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internal Medicine Clinic
Trial: 28713645
Drug: Test agent
RxNorm normalized name: Adenosine 3mg/1mL Solution for injection [Cardiac Stress Test Agent]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test agent (novel slowly dissolving adhering disc) plus oral hygiene self-care
Trial: 28713645
Drug: Oral hygiene
RxNorm normalized name: HYDROGEN PEROXIDE 2.94 mL in 2.94 mL ORAL SPRAY [OROXID Forte Oral Hygiene]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral hygiene self-care only
Trial: 25733627
Drug: Sodium intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium intake <2300 mg/d
Trial: 25733627
Drug: Increasing sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increasing sodium intake >2300 mg/d
Trial: 22850357
Drug: Participants with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants with antihypertensive treatment
Trial: 22850357
Drug: Participants with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants with glomerular filtration rate 60-90 ml/min per 1.73 m²
Trial: 22850357
Drug: Participants with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants with glomerular filtration rate < 60 ml/min per 1.73 m²
Trial: 21663813
Drug: Landiolol (0.125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Landiolol (0.125 mg/kg/min for one minute and then 0.04 mg/kg/min)
Trial: 19634511
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation of clopidogrel
Trial: 19634511
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation of clopidogrel
Trial: 16702890
Drug: Sertraline (25-200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline (25-200 mg/d)
Trial: 16563996
Drug: Single-dose brachytherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose brachytherapy (12 Gy)
Trial: 8450402
Drug: beta-carotene, 180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: beta-carotene, 180 mg/day
Trial: 3922052
Drug: Isosorbide dinitrate
RxNorm normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide dinitrate ointment (100 mg)
Trial: 31232639
Drug: SIT (sprint
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SIT (sprint interval training) - twice‐weekly all‐out effort cycle sprints consisting of 6 × 10 s sprint with 80 s recovery
Trial: 29310617
Drug: Exercise group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise group (n=36): 3 weekly sessions of 35 min moderate intensity walking/running followed by 25 min resistance training
Trial: 26704739
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose condition
Trial: 26704739
Drug: High plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High plasma drug levels
Trial: 26704739
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual control sample (n = 128)
Trial: 24907875
Drug: Ondansetron (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron (8 mg, 2 mL)
Trial: 24907875
Drug: Placebo (0.9%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (0.9% saline, 2 mL)
Trial: 8179131
Drug: Pancuronium 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pancuronium 0.2 mg.kg‐1
Trial: 8179131
Drug: Pipecuronium 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pipecuronium 0.2 mg.kg‐1
Trial: 6113682
Drug: 2 ml
RxNorm normalized name: ethanol 2 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 ml saline (control)
Trial: 23357152
Drug: Ferric Carboxymaltose
RxNorm normalized name: Ferric Carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ferric Carboxymaltose (FCM, 500-1000 mg as single shot infusion over 20 min)
Trial: 23357152
Drug: Ferric Gluconate
RxNorm normalized name: Ferric Gluconate
DrugBank: Ferrous gluconate (DB14488)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ferric Gluconate (FG, 62.5 mg once weekly)
Trial: 17521392
Drug: Astaxanthin 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Astaxanthin 40 mg daily
Trial: 15496219
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg donepezil (single dose)
Trial: 15496219
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg donepezil (multiple doses for 23 days)
Trial: 15496219
Drug: Healthy controls
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Healthy controls (5 mg donepezil, single dose)
Trial: 15496219
Drug: Healthy controls
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Healthy controls (5 mg donepezil, multiple doses for 23 days)
Trial: 9609589
Drug: Unopposed estrogen
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unopposed estrogen replacement therapy
Trial: 9609589
Drug: Estrogen plus
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen plus progestin hormone replacement therapy
Trial: 9609589
Drug: Progestin addition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Progestin addition to estrogen therapy
Trial: 7816793
Drug: Tolfenamic acid
RxNorm normalized name: Tolfenamic acid
DrugBank: Tolfenamic acid (DB09216)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolfenamic acid (200 mg t.i.d.)
Trial: 7816793
Drug: Mefenamic acid
RxNorm normalized name: Mefenamic Acid
DrugBank: Mefenamic acid (DB00784)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mefenamic acid (500 mg t.i.d.)
Trial: 5337269
Drug: Treatment A
RxNorm normalized name: Nix Ultra Lice Treatment And Prevention Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment A (green and yellow gelatin capsule filled with lactose)
Trial: 5337269
Drug: Treatment B
RxNorm normalized name: PanOxyl Acne Treatment Bar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment B (red and white capsule containing lactose)
Trial: 30566941
Drug: Ruxolitinib 20
RxNorm normalized name: ruxolitinib 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ruxolitinib 20 mg twice daily
Trial: 24550168
Drug: Methotrexate (MTX)
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate (MTX) 2.5 mg/week
Trial: 24550168
Drug: Methotrexate (MTX)
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate (MTX) 5 mg/week
Trial: 24550168
Drug: Methotrexate (MTX)
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate (MTX) 20 mg/week
Trial: 15328178
Drug: Arzoxifene 10
RxNorm normalized name: Arzoxifene
DrugBank: Arzoxifene (DB06249)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arzoxifene 10 mg daily
Trial: 15328178
Drug: Arzoxifene 50
RxNorm normalized name: Arzoxifene
DrugBank: Arzoxifene (DB06249)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arzoxifene 50 mg daily
Trial: 10221828
Drug: sucralfate granules
RxNorm normalized name: Sucralfate
DrugBank: Sucralfate (DB00364)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: sucralfate granules in suspension
Trial: 8174988
Drug: Intralipid 20%
RxNorm normalized name: Intralipid 20% Fat Emulsion for Injection
DrugBank: Soybean oil (DB09422)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralipid 20% (6 g/h)
Trial: 23704672
Drug: Metformin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin plus intensive lifestyle intervention
Trial: 1556754
Drug: Conjoint therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conjoint therapy
Trial: 3890528
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg of dipyridamole for 2 weeks
Trial: 25342212
Drug: Prasugrel (20/3.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prasugrel (20/3.75 mg, loading/maintenance dose)
Trial: 23277121
Drug: Brucella melitensis
RxNorm normalized name: brucella melitensis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brucella melitensis strain Rev. 1 vaccine (10(6) or 5 × 10(5) live cells)
Trial: 23277121
Drug: Brucella melitensis
RxNorm normalized name: brucella melitensis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brucella melitensis strain Rev. 1 vaccine (7.5 × 10(6) organisms)
Trial: 12375675
Drug: Diet therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet therapy and insulin as required
Trial: 7579000
Drug: glipizide (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: glipizide (2.5 mg)
Trial: 7579000
Drug: antipyrine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: antipyrine (20 mg/kg)
Trial: 7579000
Drug: coumarin (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: coumarin (5 mg)
Trial: 1657526
Drug: Long-term drug
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term drug therapy (specific drug not mentioned)
Trial: 27043535
Drug: EPO+G-CSF
RxNorm normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EPO+G-CSF
Trial: 25594755
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy plus bismuth subsalicylate
Trial: 25594755
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy plus placebo
Trial: 17714570
Drug: Ketamine with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine with intravenous patient-controlled-analgesia morphine
Trial: 10101629
Drug: Harpagophytum extract
RxNorm normalized name: Harpagophytum procumbens whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Harpagophytum extract WS 1531 (600 mg)
Trial: 10101629
Drug: Harpagophytum extract
RxNorm normalized name: Harpagophytum procumbens whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Harpagophytum extract WS 1531 (1200 mg)
Trial: 2170884
Drug: Estrone sulfate
RxNorm normalized name: Estrone sulfate
DrugBank: Estrone sulfate (DB04574)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Estrone sulfate 0.625 mg daily
Trial: 2170884
Drug: Estrone sulfate
RxNorm normalized name: Estrone sulfate
DrugBank: Estrone sulfate (DB04574)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Estrone sulfate 1.25 mg daily
Trial: 22192731
Drug: Chemotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy plus erlotinib
Trial: 23782814
Drug: Chemotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy plus erlotinib (in patients with activating EGFR gene mutation)
Trial: 23782814
Drug: Chemotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy plus placebo (in patients with activating EGFR gene mutation)
Trial: 22151975
Drug: Calcium and
RxNorm normalized name: Calcium and Magnesium
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium and vitamin D supplementation (800 IU of vitamin D and 1000 mg of calcium daily)
Trial: 14627173
Drug: Adjustable dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjustable dosing with budesonide/formoterol (Symbicort, Turbuhaler) 80/4.5 microg or 160/4.5 microg, two inhalations twice daily for four weeks, followed by adjustable maintenance dosing for six months
Trial: 14627173
Drug: Fixed dosing
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed dosing with budesonide/formoterol (Symbicort, Turbuhaler)
Trial: 9173128
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose heparin (15,000 units)
Trial: 2915651
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy (six cycles of cyclophosphamide 100 mg/m² orally on days 1-14, methotrexate 40 mg/m² intravenously on days 1 and 8, fluorouracil 600 mg/m² intravenously on days 1 and 8, and prednisone 40 mg/m² orally on days 1-14)
Trial: 2915651
Drug: No-treatment observation
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No-treatment observation (Control)
Trial: 951456
Drug: Amphetamine formulations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amphetamine formulations
Trial: 30817402
Drug: Restrictive red
RxNorm normalized name: acid red 35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Restrictive red blood cell transfusion threshold (7 g/dl)
Trial: 24983993
Drug: Onlay mesh
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Onlay mesh augmentation (OMA)
Trial: 24983993
Drug: Sublay mesh
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublay mesh augmentation
Trial: 19352162
Drug: Epidural lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural lidocaine (10 ml, 1%)
Trial: 16672092
Drug: Closed-loop group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Closed-loop group (propofol titration using a proportional differential algorithm)
Trial: 16672092
Drug: Target control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Target control infusion (TCI) group (manual propofol titration guided by Bispectral Index using Diprifusor device)
Trial: 9143797
Drug: Daily Wear
RxNorm normalized name: ZINC OXIDE 22.7 g in 100 g TOPICAL LOTION [ETHICAL ZINC DAILY WEAR LIGHT SUNSCREEN SPF-50]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily Wear (DW)
Trial: 9484362
Drug: Intravenous methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous methylprednisolone (IVMP; 1 g daily for 6 days) during rIFN beta‐1a treatment
Trial: 9484362
Drug: Intravenous methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous methylprednisolone (IVMP; 1 g daily for 6 days) without rIFN beta‐1a treatment
Trial: 8038592
Drug: High-dose TNF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose TNF in isolated limb perfusions
Trial: 8038592
Drug: TNF, IFN,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TNF, IFN, and melphalan limb perfusion with systemic high-dose interleukin-2 postoperatively
Trial: 2924980
Drug: Ketoconazole 200
RxNorm normalized name: ketoconazole 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoconazole 200 mg daily for 8 days
Trial: 2924980
Drug: Terbinafine 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbinafine 500 mg daily for 8 days
Trial: 241876
Drug: Propranolol (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (50 mg three times daily for 4 weeks)
Trial: 241876
Drug: Prindolol (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prindolol (10 mg three times daily)